K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Different mutant amino acids in the Ras proteins lead to distinct transforming capacities and different aggressiveness in human tumors. K-Ras Asp12 (K12D) is more prevalent in benign than in malignant human colorectal tumors, whereas K-Ras Val12 (K12V) associates with more advanced and metastatic carcinomas, higher recurrence and decreased survival. Here, we tested, in a nude mouse xenograft model, whether different human K-Ras oncogenes mutated at codon 12 to Val, Asp or Cys would confer NIH3T3 fibroblasts distinct oncogenic phenotypes. We studied tumor histology and growth, apoptotic and mitotic rates, activation of signal transduction pathways downstream of Ras and regulation of the cell cycle and apoptotic proteins in tumors derived from the implanted transformants. We found that the K12V oncogene induces a more aggressive tumorigenic phenotype than the K12D oncogene, whereas K12C does not induce tumors in this model. Thus, K12V mutant tumors proliferate about seven times faster, and have higher cellularity and mitotic rates than the K12D mutant tumors. A molecular analysis of the induced tumors shows that the K12V mutant protein interacts with Raf-1 and transduces signals mainly through the Erk pathway. Unexpectedly, in tumors induced by the K12D oncogene, the K-Ras mutant protein does not interact with Raf-1 nor activates the Erk canonical pathway. Instead, it transduces signals through the PI3K/Akt, JNK, p38 and FAK pathways. Finally, the higher growth rate of the K12V tumors associates with enhanced Rb phosphorylation, and PCNA and cyclin B upregulation, consistent with faster G1/S and G2/M transitions, without alteration of apoptotic regulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies with KRAS G12C , RAF, and MEK inhibitors indicated that blockade of KRAS-dependent signaling activated a transcriptional program suppressing DUSP , SPRY , and ETV family genes which cooperate to mediate increased signaling flux though RTK, SOS, and MEK/ERK family members resulting in conditional bypass dependence on KRAS [4, 32-34].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [34]
Citations
Cites
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Regarding the G1/S transition both mutants induced a similar expression of cyclin D1; the K12V may do this by signaling through the Erk pathway, whereas K12D may use at least the PI3K/Akt, JNK and p38 pathways to do so. Thus, the Raf/Erk pathway upregulates cyclin D1 ( 39 ).”
BackgroundTargeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108 · cited 1×
“the MEK1 ( 51 ) inhibitors may not work in the subset of tumors bearing K12D mutations (and possibly”
BackgroundDifferential Activation of ERK and JNK Mitogen-Activated Protein Kinases by Raf-1 and MEKK
Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Dérijard, B., Davis, R. J., Johnson, G. L., & Karin, M. (1994) · Science · doi:10.1126/science.7992057 · Cited by 1,069 · cited 1×
“Similarly, the Ras effector MEKK (34) is known to activate p38 and Jnk pathways, but not Erk ( 35 ,36).”
BackgroundRodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Liang, J., & Slingerland, J. M. (2003) · Cell Cycle · doi:10.4161/cc.2.4.433 · Cited by 885
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872 · cited 1×
“Thus, K12D is more prevalent in benign than in malignant human colorectal tumors (10), whereas K12V associates with more advanced and metastatic colorectal carcinomas (11,12), higher recurrence and decreased survival (13, 49 ).”
BackgroundTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798 · cited 1×
“This conclusion is also in agreement with the findings that transgenic (26) or ‘knock in’ (27) mice, expressing the K12V mutant, activate the Erk, but not the Akt, pathway and yield lung and intestinal carcinomas, whereas K12D ‘knock in’ mice activate the Akt, but not the Erk, pathway and yield only lung and intestina…”
ResultIdentification of a Dual Specificity Kinase That Activates the Jun Kinases and p38-Mpk2
Lin, A., Minden, A., Martinetto, H., Claret, F.-X., Lange-Carter, C., Mercurio, F., Johnson, G. L., & Karin, M. (1995) · Science · doi:10.1126/science.7716521 · Cited by 764
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Cited by
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
“In contrast, KRAS G12V, predicted to be a moderate RAF activator in our study, associated with both RAF kinase and PI3K in these cells (67).”
BackgroundAnti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
“When mutant forms of KRAS were expressed in murine fibroblasts, codon 12 alleles exhibited the strongest transforming activity, but only just slightly greater than those at codons 13, 61, 146 and 117 [50, 52, 53], possibly because codon 12 mutants were unique in their ability to promote PI3K signaling in this context…”
BackgroundA Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
“identified the tumorigenic potential of KRAS G12V and G12D mutations in vivo (27).”
BackgroundMethodInfluentialPeeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
“The G60 hotspot, identified in other cancer types30, was not found in our study; 0 189100 6 5 3 4 2 1# H R A S m ut at io ns 1 10,000 1000 100 10 # K R A S m ut at io ns 0 189100 0 189100 G12(193) E132(3) P185(4) P167(4)R161(4) G13(57) Q61(294) G13(1196) L19(13) V14(17) Q22(19) D33(9)V9(9) R68(8) G60(8) A59(44) G12(47…”
InfluentialRadiation-induced EGFR-signaling and control of DNA-damage repair
Rodemann, H. P., Dittmann, K., & Toulany, M. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701769970 · Cited by 201
“At first sight this observation is in contrast to many reports (Zhang & Lodish 2005, Cespedes et al. 2006) indicating that Ras activity, mainly triggered through EGFR-signaling is essential for direct stimulation of PI3K and its downstream effector AKT.”
ResultYoon, H. H., Tougeron, D., Shi, Q., Alberts, S. R., Mahoney, M. R., Nelson, G. D., Nair, S. G., Thibodeau, S. N., Goldberg, R. M., Sargent, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3140 · Cited by 156
Fan, H., Shimada, M., Liu, Z., Cahill, N., Noma, N., Wu, Y., Gossen, J. A., & Richards, J. S. (2008) · Development · doi:10.1242/dev.020560 · Cited by 176
“, 2007), as well as the studies of others who have shown that KRAS selectively activates RAF1 and/or PI3K in a cell- and context-specific manner (Campbell et al., 2007; Cespedes et al., 2006; Gupta et al., 2007; Tuveson et al., 2004).”
BackgroundShvedova, A. A., Yanamala, N., Kisin, E. R., Tkach, A. V., Murray, A. R., Hubbs, A., Chirila, M. M., Keohavong, P., Sycheva, L. P., Kagan, V. E., et al. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00167.2013 · Cited by 124
Protein conformational ensembles in function: roles and mechanisms
Nussinov, R., Liu, Y., Zhang, W., & Jang, H. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00114h · Cited by 136
Riquelme, E. M., Behrens, C., Lin, H. Y., Simon, G. R., Papadimitrakopoulou, V. A., Izzo, J. G., Moran, C. A., Kalhor, N., Lee, J. J., Minna, J. D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1141 · Cited by 122
“It has been found that different amino acid substitutions in mutant KRAS may have a differential effect on the oncogenic potential, suggesting heterogeneity of behavior in different KRAS mutant subtypes (20, 21).”
Toulany, M., Baumann, M., & Rodemann, H. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0297 · Cited by 109
“Some reports indicate that K-Ras activity does directly modulate AKT phosphorylation through stimulation of PI3K (60, 62), whereas others have not found a direct stimulation of AKT activity by mutated and constitutively active K-Ras protein (35, 58, 63).”
BackgroundDuldulao, M. P., Lee, W., Nelson, R. A., Li, W., Chen, Z., Kim, J., & Garcia-Aguilar, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2910-0 · Cited by 104
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
Li, W., Qiu, T., Zhi, W., Shi, S., Zou, S., Ling, Y., Shan, L., Ying, J., & Lu, N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1345-3 · Cited by 79
“Mutations in codons 12 and 13 lead to alterations in encoded amino acids adjacent to the GTP binding pocket and reduced the GTPase activity of KRAS protein after guanine nucleotide activating protein (GAP) binding [17,48-50].”
BackgroundRAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76
“Studies by Cespedes et al. (2006) have extended these findings and also confirmed the relatively weak transforming activity of the Ki-ras CYS12 allele observed in our studies.”
ResultFrumovitz, M., Burzawa, J. K., Byers, L. A., Lyons, Y. A., Ramalingam, P., Coleman, R. L., & Brown, J. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.001 · Cited by 73
“The G12D variant signals primarily through the PI3K, FAK, JNK, and p38 pathways and less dependently through RAF/ERK.[26, 27] In contrast, the G12V variant signals predominantly through the MAPK cascade and has lost the ability to bind to and signal through PI3K, specifically by blocking Akt activation.”
BackgroundOkada, M., Shibuya, K., Satō, A., Seino, S., Suzuki, S., Seino, M., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2087 · Cited by 72
“JNK was originally identified as a kinase activated by H-Ras [32, 33], but subsequently, it was demonstrated that mutated K-Ras activates JNK in vitro and in vivo [44, 45].”
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
“The in vivo study, using different KRAS mutants transformed in the NIH3T3 cells and implanted into the Nu/Nu Swiss mice, observed more aggressive tumorigenicity among the animals harboring the Kras G12V transformants compared to the Kras G12D [53].”
BackgroundResistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Blaquier, J. B., Cardona, A. F., & Recondo, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.787585 · Cited by 57
“org 2 that point mutations at codons 12 and 61 of HRAS differ in their phenotypical properties as previously reported (18), Voice et al.”
BackgroundFiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
“Several experimental studies have shown that G12V KRAS mutation possesses increased oncogenic potential and is associated with more aggressive cancer behavior compared to G12D KRAS mutation [10, 35, 36].”
BackgroundMinireview: Physiological and Pathological Actions of RAS in the Ovary
Fan, H., & Richards, J. S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0251 · Cited by 54
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Murphy, B., Terrell, E. M., Chirasani, V. R., Weiss, T. J., Lew, R. E., Holderbaum, A. M., Dhakal, A., Posada, V., Fort, M., Bodnar, M. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30881-9 · Cited by 53
Site-Dependent E-Cadherin Cleavage and Nuclear Translocation in a Metastatic Colorectal Cancer Model
Céspedes, M. V., Larriba, M. J., Pavón, M. Á., Álamo, P., Casanova, I., Parreño, M., Feliu, A., Sancho, F. J., Múñoz, A., & Mangues, R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100079 · Cited by 46
“8 clone, 1:50) and CDX2 (88 clone, Biogenex, 1:50) according to standard procedures.(26) The Snail1 antibody required target retrieval at pH 9.”
MethodSelf-citationA New View of Activating Mutations in Cancer
Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 38
“The altered conformational bias may clarify their distinct rates of GTP hydrolysis, nucleotide exchange, and phospholipid selectivity, as well as the different favored effectors; K-Ras interacts with Raf-1 and signals through MAPK and Ral guanine nucleotide dissociation stimulator (RalGDS), whereas K-Ras activates PI3…”
BackgroundSheen, M. R., Marotti, J. D., Allegrezza, M. J., Rutkowski, M. R., Conejo-Garcia, J. R., & Fiering, S. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.65 · Cited by 38
K- RAS Mutation in the Screening, Prognosis and Treatment of Cancer
Parsons, B. L., & Meng, F. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.95 · Cited by 37
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Okumura, S., & Jänne, P. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2365 · Cited by 30
Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma
Gómez‐Tomás, Á., Pumarega, J. A., Alguacil, J., Amaral, A. F. S., Malats, N., Pallarés, N., Gasull, M., Porta, M. S., & for the PANKRAS II Study Group (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22296 · Cited by 32
Conformational Dynamics Allows Sampling of an “Active-like” State by Oncogenic K-Ras-GDP
Grudzien, P. K., Jang, H., Leschinsky, N., Nussinov, R., & Gaponenko, V. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167695 · Cited by 31
Parsons, B. L., Manjanatha, M. G., Myers, M. B., McKim, K. L., Shelton, S. D., Wang, Y., Gollapudi, B. B., Moore, N. P., Haber, L. T., & Moore, M. M. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft190 · Cited by 30
Clinical relevance of KRAS mutations in codon 13: Where are we?
Er, T., Chen, C.-C., Bujanda, L., & Herreros‐Villanueva, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.012 · Cited by 29
Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer
Sun, W.-B., Wang, Y., Lei, F., Rong, W., & Zeng, Q. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s80017 · Cited by 29
“Cells harboring KRAS G12V are reported to have high oncogenic potential and are more aggressive than those harboring other KRAS mutations.(11) Patients with KRAS-mutant tumors rarely benefit from anti-EGFR therapy.”
RetractedWeidlich, S., Walsh, K., Crowther, D., Burczynski, M. E., FEUERSTEIN, G. Z., CAREY, F. A., Steele, R. J., Wolf, C. R., Miele, G., & Smith, G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.197 · Cited by 27
Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., Lund‐Iversen, M., Brustugun, O. T., Førde, D., Paulsen, E., et al. (2021) · Cancers · doi:10.3390/cancers13174294 · Cited by 26
“G12C also has a high preference for RalGDS-RalA/B while G12D has been associated with preference for interaction with PI3K/Akt [19,20].”
BackgroundInfluentialMolecular genetic profiling of small cell lung carcinoma in a Chinese cohort
Wang, Z., Jiang, Z., & Lu, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.01.26 · Cited by 22
“3% in all SCLCs), and this variation was mainly carcinogenic as identified via the PI3K-AKT, JNK, p38, and FAK signaling pathways (17,18).”
BackgroundKRAS Mutant Tumor Subpopulations can Subvert Durable Responses to Personalized Cancer Treatments
Parsons, B. L., & Myers, M. B. (2013) · Personalized Medicine · doi:10.2217/pme.13.1 · Cited by 22
Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies
Daya, T., Breytenbach, A., Gu, L., & Kaur, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2024.159578 · Cited by 21
Actionability classification of variants of unknown significance correlates with functional effect
Johnson, A. M., Ng, P. K., Kahle, M., Castillo, J., Amador, B. E., Wang, Y., Zeng, J., Holla, V. R., Vu, T. M., Su, F., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00420-w · Cited by 20
Takekuma, M., Wong, K., & Coleman, R. L. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0026-5 · Cited by 20
“G12D variant signals primarily through PI3K, JNK, p38, and FAK signaling pathways [17, 18] but signals less through the RAF/ERK pathway.”
Backgroundda Luz, F. A. C., Araújo, B. J., & de Araújo, R. A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103781 · Cited by 19
Lorentzen, J. A., Grzyb, K., Angelis, P. M. D., Hoff, G. S., Eide, T. J., & Andresen, P. A. (2016) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s40143 · Cited by 18
Khandakar, G. I., Satoh, R., Takasaki, T., Fujitani, K., Tanabe, G., Sakai, K., Nishio, K., & Sugiura, R. (2022) · Cells · doi:10.3390/cells11040702 · Cited by 17
“Moreover, the KRAS G12D mutant found in PANC-1 preferably activates AKT signaling as compared with ERK signaling [31,32].”
BackgroundThe dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations
Abdelkarim, H., Leschinsky, N., Jang, H., Banerjee, A., Nussinov, R., & Gaponenko, V. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.06.008 · Cited by 15
Lindholm, H., Ejeskär, K., & Szekeres, F. L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158237 · Cited by 14
Varga, D., Hajdinák, P., Makk‐Merczel, K., & Szarka, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911004 · Cited by 14
“It is worth noting that the KRAS G12D mutation, the most common mutant allele in pancreatic cancers [40], has been shown to preferentially activate the JNK pathway [38].”
BackgroundDifferences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations
Kun, E., Tsang, Y. T. M., Lin, S., Pan, S., Medapalli, T., Malpica, A. L., Richards, J. S., Gershenson, D. M., & Wong, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77666-y · Cited by 13
CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model
Gao, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1279 · Cited by 12
“several laboratories have demonstrated mutation-specific effects of different mutagenic rAs alleles on lung tumorigenesis in a variety of murine and cell culture models (26-34).”
Fancelli, S., Caliman, E., Mazzoni, F., Paglialunga, L., Michelet, M. R. G., Lavacchi, D., Berardi, R., Mentrasti, G., Metro, G., Birocchi, I., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968064 · Cited by 11
Wong, G. Y. M., Diakos, C. I., Molloy, M. P., & Hugh, T. J. (2022) · Cancers · doi:10.3390/cancers14133223 · Cited by 11
“Specific KRAS mutations are associated with different biologic characteristics and may have prognostic implications as suggested by variation in survival outcomes after resection in CRLM [45].”
BackgroundEvaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Sisler, D. J., Hinz, T. K., Le, A. T., Kleczko, E. K., Nemenoff, R. A., & Heasley, L. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094123 · Cited by 11
“has lower intrinsic GTP hydrolysis (8) and cell lines expressing G12V mutations form more aggressive tumors than G12D or G12C mutations (37).”
Porta, M. S., Pumarega, J. A., Amaral, A. F. S., Genkinger, J. M., Camargo, J., Mucci, L. A., Alguacil, J., Gasull, M., Zhang, X., Morales, E., et al. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109781 · Cited by 10
“Different KRAS mutations have different downstream signaling effects (Céspedes et al., 2006; Porta et al. 2003, 2009b; Shields et al., 2000), and might differently influence prognosis.”
BackgroundOhnami, S., Maruyama, K., Chen, K., Takahashi, Y., Hatakeyama, K., Ohshima, K., Shimoda, Y., Sakai, A., Kamada, F., Nakatani, S., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04172-8 · Cited by 9
“1 3 G12V, which is predicted to be a moderate RAF activator [36], is associated with both RAF kinase and PI3K in NIH3T3 cells [37].”
BackgroundIhle, N. T. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 6
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background
Budagyan, K., & Chernoff, J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_20 · Cited by 5
Functional Analysis of Rare RAS Variants of Unknown Significance
Park, S., Ikegami, M., Kitada, R., Takamochi, K., Suzuki, K., Mano, H., & Kohsaka, S. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0188 · Cited by 4
Song, K. W., Ong, C. C., Lin, E., Lau, J., Sodir, N. M., Jin, D. X., Hutchinson, K. E., Xie, S., Tan, J., Liang, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0995 · Cited by 3
“KRAS point mutations occur in 30% to 50% of colorectal cancer, most often at the G12 and G13 codons (1, 5), and differentially influence downstream signaling (6–9).”
Sevrin, T., Strasser, L., Ternet, C., Junk, P., Caffarini, M., Prins, S., D'Arcy, C., Catozzi, S., Oliviero, G., Wynne, K. J., et al. (2022) · iScience · doi:10.1016/j.isci.2023.105931 · Cited by 3
Functional distinction in oncogenic Ras variant activity in Caenorhabditis elegans
Lyu, H., & Chamberlin, H. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050577 · Cited by 3
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
“[84] In a mouse model, lung adenocarcinomas driven by KRAS G12C mutation rely more on RAL pathways to stimulate cell growth than do KRAS wt , and the KRAS G12C mutation induces greater ERK1/2 phosphorylation and responds better to MEK inhibition than cells with the KRAS G12D mutation.”
Functional differences drive the selection of NRAS mutants in melanomaPreprint
Murphy, B., Weiss, T. J., Holderbaum, A. M., Dhakal, A., Fort, M., Bodnar, M. S., Chen, M., Burd, C. J., Coppola, V., & Burd, C. E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.15.426808 · Cited by 1
“also influence effector interactions (Céspedes et al. 2006; Buhrman et al. 2007; Stolze et al. 2014; Hunter et al. 2015; Marcus and Mattos 2015) as evidenced by the positioning of switch II in KRAS12R, which prevents PI3Kα binding and the subsequent induction of macropinocytosis (Hobbs et al.”
BackgroundGenetic alterations and sensitivity to anti-cancer drugs in colorectal cancer cells
권연주 (2015) · Seoul National University Open Repository (Seoul National University)
Exploring allelic differences in KRAS mutant CRC
Budagyan, K., & Chernoff, J. (2023) · iDEA - Drexel University Institutional Repository · doi:10.17918/00001573
Linscott, M. P., Ren, J. R., Gestl, S. A., & Gunther, E. J. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.02.018
Üveges, E., Gaál, A., Szakács, G., Bakos, É., Streli, C., Kregsamer, P., Baranyi, M., Hegedűs, B., & Szoboszlai, N. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05171-w
“The signaling characteristic of G12V cells specifi - cally favors the RalGDS and MAPK/ERK (via Raf-1) signaling pathways, whereas the G12D mutant promotes a more pronounced activation of the PI3K-AKT-mTOR signaling pathway [51 ].”
Huang, M., & Li, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156783
“…kinase (JNK), with minimal reliance on the rapidly accelerated fibrosarcoma (RAF)/extracellular regulated protein kinase (ERK) pathway [107,108], whereas the G12V variant relies on mitogen-activated protein kinase (MAPK) cascade signaling and loses the ability to bind and signal through…”
Bambach, N. E., Labella, K., Jolly, L. A., Cruz, D. I., Massoll, N. A., Cristofano, A. D., & Franco, A. T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.09.750413
Sisler, D. J., Hinz, T. K., Le, A. T., Kleczko, E. K., Nemenoff, R. A., & Heasley, L. E. (2023) · doi:10.3389/fonc.2023.1094123.s001
KRAS und BRAF Mutationen im lokal fortgeschrittenen Rektumkarzinom
Obermeyer, C. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1541
Metadata
- Authors
- Cespedes, M. V., Sancho, F. J., Guerrero, S., Parreno, M., Casanova, I., Pavon, M. A., Marcuello, E., Trias, M., Cascante, M., Capella, G., & Mangues, R.
- Affiliations
- Parc Científic de Barcelona (ES)
- Hospital de Sant Pau (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Corresponding author
- Mangues, R.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-05-16
- Volume
- 27
- Issue
- 11
- Pages
- 2190-2200
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2163193780
- Cited by
- 67
- References
- 50
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 11 · 2021: 6 · 2020: 2 · 2019: 4 · 2017: 1 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 5 · 2012: 4
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- K-ras codon 12 mutation, oncogenic Ras, ERK signaling, PI3K/Akt signaling, JNK, p38 MAPK, focal adhesion kinase, retinoblastoma protein phosphorylation, cell cycle regulation, tumor growth rate, apoptosis, tumorigenicity, colorectal cancer, NIH3T3 cells, nude mouse xenograft
- MeSH terms
- Animals, Aspartic Acid, Male, Mice, Nude, Mutation, Neoplasm Metastasis, Protein Binding, Valine, Signal Transduction, Oncogene Protein p21(ras), Apoptosis, Proto-Oncogene Proteins c-raf, NIH 3T3 Cells, Extracellular Signal-Regulated MAP Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.